Rescue immunosuppression with mammalian target of rapamycin inhibitor drugs in liver transplantation.
Mártinez
J M A
JM
Liver Transplant Unit, Virgen del Rocío Hospital, Seville, Spain. jmalamom@terra.es
Pulido
L B
LB
Bellido
C B
CB
Usero
D D
DD
Aguilar
L T
LT
Moreno
J L G
JL
Artacho
G S
GS
Díez-Canedo
J S
JS
Gómez
L M M
LM
Bravo
M A G
MA
D006528:Carcinoma, Hepatocellular / Q000601:surgery; D000068338:Everolimus; D006084:Graft Rejection / Q000276:immunology; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D047908:Intracellular Signaling Peptides and Proteins / Q000037:antagonists & inhibitors*; D008113:Liver Neoplasms / Q000601:surgery; D016031:Liver Transplantation / Q000276:immunology*; D009364:Neoplasm Recurrence, Local / Q000453:epidemiology; D017346:Protein Serine-Threonine Kinases / Q000037:antagonists & inhibitors*; D012449:Safety; D020123:Sirolimus / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D058570:TOR Serine-Threonine Kinases
D007166:Immunosuppressive Agents; D047908:Intracellular Signaling Peptides and Proteins; D000068338:Everolimus; C546842:MTOR protein, human; D017346:Protein Serine-Threonine Kinases; D058570:TOR Serine-Threonine Kinases; D020123:Sirolimus